Compass Pathways to participate in three investor conferences in September

Group 1 - Compass Pathways plc is a biotechnology company focused on mental health innovation, particularly through its proprietary psilocybin treatment, COMP360, which has received Breakthrough Therapy designation from the FDA and ILAP designation in the UK for treatment-resistant depression [2][3] - The company has initiated a phase 3 clinical program for COMP360 psilocybin treatment in treatment-resistant depression, marking it as the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted [3] - Previous studies, including a phase 2b study, demonstrated a statistically significant improvement in depressive symptom severity after three weeks for patients receiving a single 25mg dose of COMP360 with psychological support [3] Group 2 - Compass Pathways will participate in several investor conferences in September 2024, including the Morgan Stanley 22nd Annual Global Healthcare Conference, H. C. Wainwright 26th Annual Global Investment Conference, and Cantor Global Healthcare Conference, with live audio webcasts available [1] - The company is headquartered in London, UK, with additional offices in New York and San Francisco, and aims to promote mental wellbeing globally [4]